Introduction
============

Background
----------

Autoimmune diseases (ADs) are a heterogeneous group of diseases affecting 8--10% of the population. Therapeutic immunosuppression and novel biological therapies can suppress or attenuate the inflammatory process as long they are applied, but cannot switch off the underlying mechanisms inducing therapy-free remission, that is, cure. Although effective in most cases, chronic immunosuppression is associated with the reduction in quality-of-life, cumulative toxicity and increased risk of cardiovascular disease, and represents a considerable socioeconomic challenge. For patients with major organ involvement and therapy-resistant disease, high-dose immunosuppression followed by haematopoietic SCT has been used since 1995^[@bib1]^ worldwide and was shown to induce treatment-free, long-term remissions in several ADs.^[@bib2],\ [@bib3],\ [@bib4],\ [@bib5],\ [@bib6]^ More recently, the use of MSCs has shown promising results in chronic GVHD^[@bib7]^ and ADs,^[@bib8]^ and common procedures for immune monitoring and biobanking will be applied for these various types of SCT in AD patients.

The concept of SCT for ADs
--------------------------

On the basis of experimental data from animal models,^[@bib9],\ [@bib10]^ haematopoietic SCT for ADs is applied with the goal of eradicating the autoreactive immunologic memory and to regenerate a naive and self-tolerant immune system from haematopoietic precursors. It has remained unclear for a long time whether clinical remissions observed after haematopoietic SCT were the result of prolonged immunosuppression or the outcome of a true reconfiguration of the immune system. A number of recent immunological studies have provided the proof-of-concept that a chronic autoreactive immune system can indeed be 'reset\' into a naive and self-tolerant immune system. These data include the regeneration of naive B cells,^[@bib5],\ [@bib11]^ thymic reactivation,^[@bib5],\ [@bib12],\ [@bib13],\ [@bib14]^ the emergence of a polyclonal TCR repertoire^[@bib5],\ [@bib12],\ [@bib14]^ and restoration of Foxp3^+^ regulatory T-cell (Treg) levels.^[@bib15],\ [@bib16]^ Although interest in MSC usage was originally raised by their potential capacity to differentiate into different cell lineages, recent work showing their immunological properties has led to a revized concept, envisioning their utilization for immunomodulatory purposes. Their clinically relevant immunomodulatory potential has been demonstrated in clinical trials for GVHD^[@bib7]^ and in various types of ADs.^[@bib8]^

Rationale for the development of guidelines for immune monitoring and biobanking in AD patients after SCT
---------------------------------------------------------------------------------------------------------

Early clinical guidelines and recommendations^[@bib17]^ for SCT in ADs were recently updated.^[@bib18]^ Meanwhile, activity in the field is expanding with results from randomized phase II/III studies in major disease indications, such as systemic sclerosis (ASTIS).^[@bib2]^ In parallel, clinical trials of MSC transplantation have been growing in number.^[@bib8]^ Although the mechanisms of action of SCT in ADs have been partially elucidated, important issues remain unresolved from both clinical and scientific points of view. These include the variability associated with type of AD, patient age, continued use of immunosuppression and the effect of different transplantation techniques, for example, variable conditioning regimens and graft manipulation technology. The low number of patients transplanted at each centre requires multicentre studies under standardized conditions. The European Society for Blood and Marrow Transplantation Autoimmune Diseases and Immunobiology Working Parties have, therefore, undertaken a combined initiative to develop guidelines for harmonized 'good laboratory practice\' in biobanking and immune monitoring before and after SCT in patients with ADs. These guidelines do not replace established standard operating procedures in individual laboratories, and national regulatory requirements should always prevail. However, they aim to support the establishment of an international biobanking infrastructure and common testing protocols, thereby facilitating collaborative and comparative research studies in the field of stem cell therapies for ADs.

General recommendations
=======================

Clinical practice guidelines
----------------------------

In AD patients considered for SCT, referral should be made to a centre with appropriate inter-disciplinary interaction between haematological and AD specialists. Such centres should have JACIE accreditation or equivalent^[@bib18]^ and should provide programmes for long-term follow-up, quarterly for the first year and biannually follow-up consultation, thereafter, ideally with dual review by both haematologists and disease specialists with assessment of disease-specific activity scores. Where possible, laboratories should participate in internal and external quality assurance schemes for flow cytometry, molecular genetics and immunological markers. National and/or EU regulations should be followed in relation to biobanking of cells and tissues.

Guidelines for basic laboratory immune analyses and biological sample storage
-----------------------------------------------------------------------------

A minimum set of laboratory analyses is recommended for immune monitoring in patients before and at certain time-points after SCT by all contributing centres ([Table 1](#tbl1){ref-type="table"}). These include full blood count analysis on freshly isolated PBMCs, allowing enumeration of CD4^+^ and CD8^+^ T cells, CD19^+^ B cells, CD3^−^/CD56^+^ natural killer cells, CD3^+^/CD56^+^ natural killer-like T cells and CD14^+^ monocytes. In addition, monitoring of total Ig levels and analysis of serum autoantibody titres in Ab-mediated ADs are recommended at baseline before the mobilization and SCT, quarterly for the first year and biannually thereafter. In addition to the mentioned basic laboratory immune analyses, storage of biological samples is recommended for extended immune monitoring at later time-points. A list of biological samples recommended for storage and potential immunologic investigations is provided ([Table 2](#tbl2){ref-type="table"}). To promote harmonized sample handling across different sites, standardized protocols for sample collection, processing and storage have been developed and are provided in the [Supplementary Appendix](#sup1){ref-type="supplementary-material"}.

Expert centre recommendations for extended immune monitoring
------------------------------------------------------------

For centres with expertize in flow cytometry and adequate immune monitoring core facilities, it is recommended to analyse a broader set of biomarkers in patients before and after SCT. For immunocytometric analysis, eight panels were defined, dedicated to fine cytometric analyses of the different subsets of cells within the major cellular populations ([Table 3](#tbl3){ref-type="table"}). Comparison between centres may be possible given a preliminary calibration of all flow cytometers with the same rainbow fluorescent particles. For in-depth investigation of the T- and B-cell lymphopoiesis, it is recommended to analyse T-cell receptor excision circles^[@bib19]^ and κ-deleting recombination excision circles,^[@bib20]^ which can be measured simultaneously using duplex real-time PCR.^[@bib21],\ [@bib22]^ Furthermore, TCR repertoire analysis of peripheral blood T cells is suggested with Vbeta analysis and flow cytometry, spectratyping or high-throughput sequencing.^[@bib23]^ Providing that efficient eradication of the autoreactive memory is a prerequisite for favourable long-term responses, it is suggested to analyse the frequency of autoantigen-specific T cells before and after SCT where possible, for example, islet-Ag-specific T cells in type 1 diabetes.^[@bib24]^ Here, tetramer staining^[@bib24],\ [@bib25]^ or magnetic pre-enrichment of CD154^+^ T cells provides techniques for high-resolution analysis of Ag-reactive T cells directly from peripheral blood.^[@bib26]^ In addition, gene expression profiling of either whole blood or lymphocyte subsets, using microarray technology, at defined time-points before and after SCT should be considered ([Table 2](#tbl2){ref-type="table"}).

Implications of immune monitoring for clinical practice: recommendations for infection prophylaxis and re-vaccination
---------------------------------------------------------------------------------------------------------------------

Current Autoimmune Diseases Working Party guidelines already recommend that all patients receive *Pneumocystis jiroveci*, herpes and antifungal prophylaxis and are monitored for CMV and EBV (ideally by PCR) for infection (primary or reactivation) for at least 3 months after transplant, with active surveillance thereafter up to 2 years after SCT according to local practice.^[@bib18]^ At that stage, CD4^+^ cell counts should be repeated and, if still below 200 cells/μL, prophylaxis or quarterly monitoring should be continued. If the patient suffers from recurrent or a life-threatening infection despite neutrophil recovery and has Ig or Ig subclass deficiency, i.v. Ig substitution should be considered after weighing up the benefits, risks and costs. Given the previous and often ongoing administration of immunosuppressive drugs following SCT, measurement of specific Ab levels is recommended before and after re-vaccination when performed according to published generic guidelines^[@bib27]^ to confirm protection and administer booster vaccination in patients with inadequate response.

Disease-specific recommendations
================================

Multiple sclerosis and neuromyelitis optica
-------------------------------------------

Multiple sclerosis (MS) is the most common acquired demyelinating disease of the central nervous system. MS is the result of an autoimmune inflammatory attack initiated by T and B cells and directed against components of central nervous system myelin. Axonal damage becomes prominent in secondary progressive disease and is the main cause of irreversible disability. HLA genes have a primary role in genetic susceptibility to MS, with a predominant role from HLA-DRB1\*15 in the majority of populations.^[@bib28],\ [@bib29]^ Recent GWAS identified multiple non-MHC loci affecting the risk of developing MS.^[@bib30]^ The majority of these genes are immune related, for example, IL-2 and IL-7 receptors, CD6, CD58, IRF8, and TNFRSF1A genes. The most commonly used rating scale to grade neurological disability in patients with MS is the Expanded Disability Status Scale.^[@bib31]^ Historically considered a variant of MS, neuromyelitis optica is recognized as a distinct disease entity, whose hallmark is immune-mediated inflammation of optic nerves and the spinal cord caused by autoantibodies to the water channel aquaporin 4.^[@bib32],\ [@bib33]^ Besides being pathogenic, aquaporin 4 Abs are used as a marker of 'minimal residual AD\' after SCT.^[@bib34]^ In addition to the general guidelines and immune monitoring panels described above, specific recommendations for MS and neuromyelitis optica are provided ([Table 4](#tbl4){ref-type="table"}).

Systemic sclerosis
------------------

Systemic sclerosis (SSc) is a rare AD (prevalence 5--50 per 100 000) characterized by early endothelial vascular damage with activation of the immune response and enhanced collagen synthesis. Ag stimulation and genetic susceptibility contribute to autoimmunity, with consequent T- and B-cell activation, and fibroblast activation by pro-fibrotic cytokines, that is, transforming growth factor-β and connective tissue growth factor. Early T-cell infiltrates in skin and pulmonary tissue, autoantibody production by plasma cells, notably, anti-centromere and anti-topoisomerase-I and the presence of macrophages or altered endothelial cells promote inflammation and fibrosis. Several genetic associations have been observed between HLA types and autoantibody profiles, and genome-wide screening studies identified specific nucleotide polymorphisms in relevant genes related to SSc.^[@bib35]^ More recently, use of microarray technology showed significant differences of gene patterns in skin biopsies from patients with diffuse and limited SSc, which also differed from normal controls.^[@bib36]^ In this context, a few years ago, the EUSTAR biobanking group developed guidelines for collection, storage and distribution of SSc biospecimens ([www.eustar.org](http://www.eustar.org)). In addition to documenting a minimal essential data set, acquisition and storage of blood samples, and skin biopsies from patients with SSc after SCT are strongly encouraged in expert centres ([Table 4](#tbl4){ref-type="table"}).

Systemic lupus erythematosus
----------------------------

Systemic lupus erythematosus (SLE) is a rare chronic AD (prevalence 20--150 cases per 100 000) with heterogeneous clinical manifestations.^[@bib37]^ It is characterized by the generation of Abs directed against a variety of autoantigens, including nuclear and cytoplasmic Ags, and by complement activation.^[@bib37]^ Autoreactive plasma cells are key players in the induction and perturbation of immunopathology in SLE, and short-lived (HLA-DR^high^) plasmablasts are readily detectable in the peripheral blood of patients with active disease.^[@bib38]^ Another hallmark of SLE is the upregulation of IFN-regulated gene transcripts.^[@bib39]^ IFNα and its response proteins IP-10 and Siglec-1 are established markers for monitoring disease activity in SLE.^[@bib40]^ Circulating Foxp3^+^ Tregs are expanded in SLE, with Helios-expressing Tregs being the most prominent Treg subset, which correlates with disease activity.^[@bib41]^ Disease activity is most commonly measured by SLE disease activity index that comprises relevant clinical and laboratory values.^[@bib42]^ On the basis of these disease-specific features, recommendations for immune monitoring in SLE are provided ([Table 4](#tbl4){ref-type="table"}).

Crohn\'s disease
----------------

Crohn\'s disease is a chronic inflammatory bowel disease characterized by recurring episodes of inflammation of the gastrointestinal tract. It is thought to arise by dysregulated mucosal immune responses to the gut flora in genetically susceptible individuals.^[@bib43]^ GWAS and meta-analyses have identified 140 susceptibility loci to Crohn\'s disease in Caucasians, but their heritability is not fully explained.^[@bib44]^ Disease activity is monitored by symptom-based scores, most commonly the Harvey--Bradshaw index^[@bib45]^ and the Inflammatory Bowel Disease Questionnaire.^[@bib46]^ Recent studies revealed an altered intestinal microbial and peripheral blood T-cell phenotype, in particular involvement of Th17 cells and IL-21/IL-22-producing CD4^+^ T cells in Crohn\'s disease.^[@bib47],\ [@bib48]^ In addition, several biomarkers were shown to be important in assessment of disease, most notably serum cytokines (IL-22), metalloproteinase 9 and faecal calprotectin.^[@bib49]^ In addition to the general recommendations for immune monitoring, specific parameters of the immune system may be important in Crohn\'s disease ([Table 4](#tbl4){ref-type="table"}).

Type 1 diabetes
---------------

Type 1 diabetes mellitus is an AD caused by autoreactive CD4^+^ and CD8^+^ T cells against insulin-producing islet cells.^[@bib50]^ Although the current standard treatment is insulin replacement therapy, several clinical trials for haematopoietic SCT have demonstrated long-term, insulin- and drug-free remissions in new-onset type 1 diabetes mellitus.^[@bib4],\ [@bib51]^ Following SCT, metabolic end points such as C-peptide secretion, HbA1c level and daily insulin need should be monitored. Immunological end points can give better information on the efficacy of the immune intervention. Although no correlation with disease activity has been described between several islet-specific Abs involved in type 1 diabetes mellitus (ICA-512/IA-2, GAD65),^[@bib50],\ [@bib52]^ their prognostic and predictive value in the context of SCT remains to be determined. Monitoring T-cell responses after SCT may be more relevant. Here, tetramer-staining techniques allow testing T-cell responses to HLA-A2-restricted insulin B10, pre-pro-insulin, islet Ag, GAD65 and pre-pro islet amyloid polypeptide.^[@bib24],\ [@bib25]^ We recommend also considering the publication of the T-cell workshop initiative of the Immunology of Diabetes Society regarding guidelines on how to handle biological samples in clinical type 1 diabetes mellitus trials.^[@bib53],\ [@bib54]^

Rheumatoid arthritis and juvenile idiopathic arthritis
------------------------------------------------------

Rheumatoid arthritis (RA), affecting \~1% of the population, is characterized by chronic joint inflammation, autoantibody production and variable degrees of bone and cartilage erosion.^[@bib55]^ Disease activity can be measured using the Disease Activity Scores and Clinical Disease Activity Index.^[@bib56]^ Immunopathology includes break of tolerance and accumulation of immune effector cells including macrophages and osteoclasts, DCs, B and T cells, especially Th17 subsets. Reduced T-cell receptor excision circles and shortened telomeres result in a contracted TCR repertoire in both naive and memory T cells.^[@bib57],\ [@bib58]^ Haematopoietic SCT was applied as a salvage therapy in severely affected patients in the 'pre-biologic era\'. Although remission occurred in the majority of cases, recurrence was common, irrespective of CD34^+^ graft selection.^[@bib59],\ [@bib60]^ In JIA patients undergoing Auto-SCT, restoration of initially reduced Foxp3^+^ Treg levels was observed with change in autoreactive T cells from a pro-inflammatory (IFN-gamma and T-bet high) to a tolerant phenotype (IL-10 and GATA-3 high) after SCT.^[@bib15]^ Disease-specific recommendations for immune monitoring in RA/JIA are provided ([Table 4](#tbl4){ref-type="table"}).

Conclusions
===========

Although activity in the field of SCT for ADs is rapidly expanding, the interpretation of results obtained from immune monitoring of clinical trials is often limited due to the heterogeneity of methods that are used for sample processing and analysis. With the guidelines provided here, we aim to define 'good laboratory practice\' in handling of biological samples and to harmonize methods for preparation, storage and analysis of biological specimens for immune reconstitution studies. The implementation and dissemination of these guidelines aim to support the establishment of an international biobanking infrastructure and common testing protocols. Adequate reporting and connection between the individual centres exploiting these data will foster collaborative and comparative research studies throughout Europe for better patient care and to refine our understanding of the underlying mechanisms of action that may directly translate into optimized protocols for SCT in ADs.

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies this paper on Bone Marrow Transplantation website (http://www.nature.com/bmt)
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###### 

Click here for additional data file.

###### Minimum requirements for immune monitoring before and after SCT in AD patients

  *Biological sample*                                             *Recommended analyses*                        *Methods*                                            *Time-point of analysis*
  ------------------------------------------ ----------------------------------------------------------------- ----------- ------------------------------------------------------------------------------------------------------------
  Serum                                                       Total Ig levels (IgG, IgA, IgM)                     ELISA     At baseline before the mobilization and SCT, at (3), 6, (9), 12 months after SCT and biannually thereafter
  Autoantibody titres (in Ag-mediated ADs)                       ELISA, immunofluorescence                                                                                       
  PBMCs                                       Expression analysis of CD45, CD3, CD4, CD8, CD19, CD56 and CD14   Cytometry                                                        

Brackets indicate optional time-points for analysis.

###### Recommendation for storage of biological samples and their potential exploitation for immunologic investigations before and after SCT in AD patients

  *Biological sample*                                    *Potential analyses*                                                                         *Time-point of cryopreservation*
  --------------------- --------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  Serum                  Proteomic profiling, cytokines, growth factors, autoantibodies, circulating microRNAs   At baseline before the mobilization and SCT, at (3), 6, (9), 12 months after SCT and biannually thereafter
  PBMCs                                                  Cytometric profiling                                                                                         
  DNA                             Genome-wide association studies, epigenetic analysis, TRECs & KRECs                                                                 
  RNA                                          Gene expression profiles, microRNA arrays                                              At baseline before the mobilization and SCT and yearly after SCT

Abbreviations: KRECs=κ-deleting recombination excision circles; TRECs=T-cell receptor excision circles.

Brackets indicate optional time-points for analysis.

###### Panels for flow cytometric analyses

  *Panel*                                                *Analysis of markers*                                                        *Time-point of analysis*
  ---------------------------------------- -------------------------------------------------- --------------------------------------------------------------------------------------------------------
  T-cell differentiation                     CD4, CD8, CD45RA, CD31, CCR7 CD28, CD27, CD57     At baseline before the mobilization and SCT, at (3), 6, (9), 12 months after SCT and yearly thereafter
  T-cell receptor subsets and activation    CD4, CD8, TCRab, TCRgd, CD69, CD38, CD45RA, CD25                                                      
  Regulatory T cells                          CD4, CD8, Foxp3, CD25, CD127, CD45RA, Ki-67                                                         
  B cells                                           CD19, IgD, IgM, CD27, CD38, CD24                                                              
  Plasma cells                                   CD19, CD27, CD20, CD38, CD138, HLA-DR                                                            
  DCs                                              CD45, CD11c, HLA-DR, BDCA-2, CD86                                                              
  MSC                                       CD45, CD34, CD80, CD86, CD73, CD90, CD105, CD271                                                      
  Master transcription factors                   CD3, CD4, T-bet, GATA-3, RORγt, Bcl-6                                                            

Brackets indicate optional time-points for analysis.

###### Disease-specific recommendations for immune monitoring before and after SCT in AD patients

  *Autoimmune disease*                                            *Biological sample*                                                          *Recommended analyses*                                                                       *Methods*                                                                 *Time-point of analyses*
  -------------------------------------------------------- ---------------------------------- ------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  Multiple sclerosis and neuromyelitis optica                            Serum                                                Autoantibodies: Anti-aquaporin 4 (only in NMO patients)                                               ELISA, immunofluorescence                At baseline before the mobilization and SCT, at (3), 6, (9), 12 months after SCT and biannually thereafter
                                                                                                                                              Abs against viruses: JCV                                                                        ELISA                                                                               
                                                                         PBMCs                                              MAIT cells: CD3, CD4, CD8, CD161, TCRVa7.2, CCR6 and IL-18R                                                        FACS                            At baseline before the mobilization and SCT, at (3), 6, (9), 12 months after SCT and yearly thereafter
                                                                                                                             Tregs: CD3, CD4, CD8, CD103, CD25, CD62L, Foxp3 and CD127                                                         FACS                                                                               
                                                                  Cerebrospinal fluid               Oligoclonal bands, IgG and IgM (also in matched serum), differential cell count, storage of cell pellet RNA                  Immunofixation, electrophoresis                              At baseline before the mobilization and SCT, and 12 months following SCT
                                                                                                                                                                                                                                                                            
  Systemic sclerosis                                                     Serum                                                               Complement levels: C3, C4                                                                        ELISA                          At baseline before the mobilization and SCT, at (3), 6, (9), 12 months after SCT and biannually thereafter
                                                                                                                  Autoantibodiy titres: Anti-centromere, anti-topoisomerase-I and anti-polymerase                                             ELISA                                                                               
                                                                     Skin biopsies                                                    Phenotype of leukocytes and fibroblasts                                                         FACS, immunohistology                                   At baseline before the mobilization or SCT, and 12 months following SCT
                                                                                                                                              Gene expression analysis                                                                      Microarray                                                                            
                                                                                                                                                    Fibroblasts                                                                         Fibroblast culture                                                                        
                                                                                                                                                                                                                                                                            
  Systemic lupus erythematosus                                           Serum                                                              Complement levels: C3 and C4                                                                      ELISA                          At baseline before the mobilization and SCT, at (3), 6, (9), 12 months after SCT and biannually thereafter
                                                                                                               Autoantibody titres: Anti-dsDNA, Abs to extractable nuclear Ags, anti-Cardiolipin Abs                                ELISA, immunofluorescence                                                                     
                                                                                                                                     IFNα or IFN response proteins, e.g., IP-10                                                               ELISA                                                                               
                                                                         PBMCs                                                       Tregs: CD4, Foxp3, CD25, Helios and Ki-67                                                                 FACS                            At baseline before the mobilization and SCT, at (3), 6, (9), 12 months after SCT and yearly thereafter
                                                                                                                                      Siglec-1 expression on CD14^+^ monocytes                                                                 FACS                                                                               
                                                                                                                         Low-density granulocytes: CD11b, CD15, CD16, CD33, CD86 and HLA-DR                                                    FACS                                                                               
                                                                                                                                                                                                                                                                            
  Crohn\'s disease                                                       Serum                                                          Cytokines: IL-17A, IL-22, IL-6, IFNγ                                                                  ELISA                          At baseline before the mobilization and SCT, at (3), 6, (9), 12 months after SCT and biannually thereafter
                                                                                                                                             Matrix metalloproteinase 9                                                                       ELISA                                                                               
                                                                         Faeces                                                                     Calprotectin                                                                              ELISA                                                                               
                                                                         PBMCs                                                 Activated T cells: CD4, CD38, CD45RA, HLA-DR and Ki-67                                                          FACS                            At baseline before the mobilization and SCT, at (3), 6, (9), 12 months after SCT and yearly thereafter
                                                                                                                                         Th17 T cells: CD4, IL-17 and IL-22                                                FACS after polyclonal stimulation *in vitro*                                                           
                                                                  Intestinal biopsies                                                         Phenotype of leukocytes                                                                 FACS, immunohistology                                      At baseline before the mobilization or SCT and 12 months after SCT
                                                                                                                                              Gene expression analysis                                                                      Microarray                                                                            
                                                                                                                                                                                                                                                                            
  Type 1 diabetes                                                        Serum                                                    Autoantibodies: anti-GAD65, IA-2 antibody titres                                                            ELISA                          At baseline before the mobilization and SCT, at (3), 6, (9), 12 months after SCT and biannually thereafter
                                                                                                                                                       HbA1c                                                                                  ELISA                                                                               
                                                                                                                                  C-peptide secretion (mixed meal tolerance test)                                                             ELISA                                                                               
                                                                         Other                                                                    Insulin need/kg                                                                                                                                                                 
                                                                         PBMCs                 Islet autoreactive T cells: CD4^+^ and CD8^+^ T cells specific for GAD65, insulin (B9-23), and IA-2 (709-736) peptides           FACS after *in vitro* stimulation                         At baseline before the mobilization and SCT, at (3), 6, (9), 12 months after SCT
                                                                                                                                                                                                                                                                            
  Rheumatoid arthritis and juvenile ideopathic arthritis                 Serum                                 Autoantibodies: rheumatoid factor (RF), anti-cyclic *citrullinated peptide* (anti-CCP)                                         ELISA                          At baseline before the mobilization and SCT, at (3), 6, (9), 12 months after SCT and biannually thereafter
                                                                         PBMCs                                                                 TCR Vβ family analysis                                                                          FACS                                               At baseline before the mobilization and SCT and yearly after SCT
                                                                                                                                              Telomere length analysis                                                                   Quantitative PCR                                                                         
                                                            Synovial fluid mononuclear cells                                              Lymphocyte number and phenotype                                               FACS, immunohistology, microscopic synovitis score             At baseline before the mobilization or SCT and 12 months following SCT (if applicable)

Abbreviation: NMO=neuromyelitis optica.

Brackets indicate optional time-points for analysis.
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